All In Biotech

Drug Trial Radar · NCT00856206

Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate- Lowering Therapy

Last checked: Nov 20, 2026Latest source record: Apr 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,315 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,315

Actual

Start

Mar 2009

Primary completion

Jan 2011

Study completion Jan 2011

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Mar 5, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical research study is to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are on urate-lowering therapy. Subjects will participate in this study for approximately 20 weeks. Rilonacept is being studied for use in preventing gout flares in subjects on urate-lowering therapy.

Conditions

  • Gout

Interventions

  • RilonaceptBiological

    Rilonacept 160 mg subcutaneous injection once a week

  • PlaceboOther

    Placebo subcutaneous injection once a week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline up to Week 20

Locations

124 sites in 6 countries. Site status is shown where the registry gives one.

  • Site not named

    Alabaster, Alabama

  • Site not named

    Mesa, Arizona

  • Site not named

    Burbank, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Upland, California

  • Site not named

    Brooksville, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    DeBary, Florida

  • Site not named

    DeLand, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Naples, Florida

  • Site not named

    Palm Harbor, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Canton, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Sandy Springs, Georgia

  • Site not named

    Stockbridge, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Brownsburg, Indiana

  • Site not named

    Evansville, Indiana

  • Site not named

    Greenfield, Indiana

  • Site not named

    Bowling Green, Kentucky

  • Site not named

    Elizabethtown, Kentucky

  • Site not named

    Lexington, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Bingham Farms, Michigan

  • Site not named

    Brooklyn Center, Minnesota

  • Site not named

    Richmond Heights, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Billings, Montana

  • Site not named

    Kalispell, Montana

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Elizabeth, New Jersey

  • Site not named

    Albuquerque, New Mexico

Showing 40 of 124 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.